Download PDF
Z Gastroenterol 2017; 55(09): 881-882
DOI: 10.1055/s-0043-117060
Kommentiertes Referat
© Georg Thieme Verlag KG Stuttgart · New York

FLOT ist Chemotherapiestandard bei Adenokarzinomen des gastroösophagealen Übergangs und Magens in der Neoadjuvanz

FLOT becomes standard neoadjuvant chemotherapy for adenocarcinoma of the esophagogastric junction and stomach
Christoph Treese
,
Hannah Harloff
,
Severin Daum
Further Information

Publication History

Publication Date:
12 September 2017 (online)

Also available at
    Permissions and Reprints

Al-Batran S et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 2016; 17(12): 1697 – 1708

Al-Batran S et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. J Clin Oncol 2017; 35, no. 15 suppl. (May 2017) 4004 – 4004